ACAT inhibitors for anti-atherosclerosis purpose
| Inhibitors | Ki (μmol/L) | Status | |
|---|---|---|---|
| ACAT1 | ACAT2 | ||
| CI976 | 5.9 | 2.1 | Failed at pre-clinical stage (Parke-Davis) |
| ATR101 (nevanimibe) | 0.23 | Failed at pre-clinical stage (Parke-Davis) | |
| CP113818 | 0.02 | 0.02 | Failed at pre-clinical stage (Pfizer) |
| CI1011 | 19 | 19 | Abandoned after phase 3 (Pfizer) |
| CS505 (pactimibe) | 4.9 | 3 | Abandoned after phase 3 (Sankyo) |
| K604 | 0.45 | 102.9 | Abandoned after phase 2 trial (Kowa) |
| F12511 | 0.039 | 0.11 | Abandoned after phase 1 trial (Lilly) |